Drug Resistance in Cancer: An Overview

Zahreddine, 2013, Mechanisms and insights into drug resistance in cancer, Front. Pharmacol., 4, 28, 10.3389/fphar.2013.00028

Sampath, 2006, Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial, Blood, 107, 2517, 10.1182/blood-2005-08-3351

Michael, 2005, Tumoral drug metabolism: Overview and its implications for cancer therapy, J. Clin. Oncol., 23, 205, 10.1200/JCO.2005.02.120

Plastaras, 2000, Xenobiotic-metabolizing cytochromes P450 convert prostaglandin endoperoxide to hydroxyheptadecatrienoic acid and the mutagen, malondialdehyde, J. Biol. Chem., 275, 11784, 10.1074/jbc.275.16.11784

Shen, 2007, Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17, Drug Metab. Dispos., 35, 1292, 10.1124/dmd.107.015354

2006, Cytochrome P450 pharmacogenetics and cancer, Oncogene, 25, 1679, 10.1038/sj.onc.1209377

Mehta, K., Bates, S.E., and Siddik, Z.H. (2009). Drug Resistance in Cancer Cells, Springer.

Rivlin, 2011, Mutations in the p53 tumor suppressor gene, Genes Cancer, 2, 466, 10.1177/1947601911408889

Aas, 1996, Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients, Nat. Med., 2, 811, 10.1038/nm0796-811

Soengas, 1999, Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition, Science, 284, 156, 10.1126/science.284.5411.156

Townsend, 2003, The role of glutathione-S-transferase in anticancer drug resistance, Oncogene, 22, 7369, 10.1038/sj.onc.1206940

Manolitsas, 1997, No association of a 306 bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer, Br. J. Cancer, 75, 1397, 10.1038/bjc.1997.238

Cumming, 2001, Fanconi anemia group C protein prevents apoptosis in hematopoietic cells through redox regulation of GSTP1, Nat. Med., 7, 814, 10.1038/89937

Holohan, 2013, Cancer drug resistance: An evolving paradigm, Nat. Rev., 13, 714, 10.1038/nrc3599

Gagnon, 2006, Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer, Clin. Cancer Res., 12, 1850, 10.1158/1078-0432.CCR-05-2130

Stavrovskaya, 2000, Cellular mechanisms of multidrug resistance of tumor cells, Biochemistry (Mosc.), 65, 95

Hinds, 1991, Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine resistant form of topoisomerase II, Cancer Res., 51, 4729

Zwelling, 1989, Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug resistant form of topoisomerase II, J. Biol. Chem., 264, 16411, 10.1016/S0021-9258(19)84722-1

Slamon, 1989, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 4905, 707, 10.1126/science.2470152

Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N. Engl. J. Med., 344, 783, 10.1056/NEJM200103153441101

Bell, 2005, Inherited susceptibility to lung cancer may be associated with the T790 drug resistance mutation in EGFR, Nat. Genet., 37, 1315, 10.1038/ng1671

Kobyashi, 2005, EGFR mutation and resistance of non-small cell lung cancer to gefitinib, N. Engl. J. Med., 352, 786, 10.1056/NEJMoa044238

Chen, 2008, Oncogenic mutations of ALK kinase in neuroblastoma, Nature, 7215, 971, 10.1038/nature07399

Zhang, 2008, 5-Fluorouracil: Mechanisms of resistance and reversal strategies, Molecules, 13, 1551, 10.3390/molecules13081551

Palmberg, 1997, Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade, Eur. J. Urol., 31, 216, 10.1159/000474453

Dieras, 2007, Trastuzumab (Herceptin) and breast cancer: Mechnisms of resistance, Bull Cancer, 94, 259

Berns, 2007, A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer, Cancer Cell, 12, 395, 10.1016/j.ccr.2007.08.030

Browne, 2011, Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells, Ann. Oncol., 22, 68, 10.1093/annonc/mdq349

Razis, 2011, Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer, Breast Cancer Res. Treat., 128, 447, 10.1007/s10549-011-1572-5

Gorre, 2001, Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification, Science, 293, 876, 10.1126/science.1062538

Asmaa, 2014, Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells, Asian Pac. J. Cancer Prev., 15, 4555, 10.7314/APJCP.2014.15.11.4555

Hirayama, 2008, Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells, Pharm. Res., 25, 827, 10.1007/s11095-007-9376-3

Nambu, 2010, Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells, Cancer Sci., 101, 137, 10.1111/j.1349-7006.2009.01365.x

Shou, 2004, Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer, J. Natl. Cancer Inst., 96, 926, 10.1093/jnci/djh166

Massarweh, 2008, Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function, Cancer Res., 68, 826, 10.1158/0008-5472.CAN-07-2707

Chang, 2001, Structure of MsbA from E. coli: A homolog of the multidrug resistance ATP binding cassette (ABC) transporters, Science, 293, 1793, 10.1126/science.293.5536.1793

Sauna, 2001, Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes, J. Biol. Chem., 276, 11653, 10.1074/jbc.M011294200

Borst, 2002, Mammalian ABC transporters in health and disease, Annu. Rev. Biochem., 71, 537, 10.1146/annurev.biochem.71.102301.093055

Schinkel, 1994, Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs, Cell, 77, 491, 10.1016/0092-8674(94)90212-7

Gottesman, 2002, Multidrug resistance in cancer: Role of ATP-dependent transporters, Nat. Rev. Cancer, 2, 48, 10.1038/nrc706

Szakas, 2004, Predicting drug sensitivity and resistance: Profiling ABC transporter genes in cancer cells, Cancer Cell, 6, 129, 10.1016/j.ccr.2004.06.026

Hilgendorf, 2007, Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines, Drug Metab. Dispos., 35, 1333, 10.1124/dmd.107.014902

Abolhoda, 1999, Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin, Clin. Cancer Res., 5, 3352

Haber, 2006, Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of neuroblastoma, J. Clin. Oncol., 24, 1546, 10.1200/JCO.2005.01.6196

Yanase, 2004, Gefitinib reverses breast cancer resistance protein-mediated drug resistance, Mol. Cancer Ther., 3, 1119, 10.1158/1535-7163.1119.3.9

Doyle, 1998, A multidrug resistance transporter from human MCF-7 breast cancer cells, Proc. Natl. Acad. Sci. USA, 95, 15665, 10.1073/pnas.95.26.15665

Imai, 2005, Estrogenmediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2, Cancer Res., 65, 596, 10.1158/0008-5472.596.65.2

Mutoh, 2006, Estrogen-mediated post transcriptional downregulation of P-glycoprotein in MDR1-transduced human breast cancer cells, Cancer Sci., 97, 1198, 10.1111/j.1349-7006.2006.00300.x

Katayama, 2007, Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein, Mol. Cancer Ther., 6, 2092, 10.1158/1535-7163.MCT-07-0148

Fukuyo, 2010, Geldanamycinand its anticancer activities, Cancer Lett., 290, 24, 10.1016/j.canlet.2009.07.010

Bonanno, 2014, Platinum drugs and DNA repair mechanism in lung cancer, Anticancer Res., 34, 493

Olaussen, 2006, DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy, N. Engl. J. Med., 355, 983, 10.1056/NEJMoa060570

Selvakumaran, 2003, Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines, Cancer Res., 63, 1311

Curtin, 2012, DNA repair dysregulation from cancer driver to therapeutic target, Nat. Rev., 12, 801, 10.1038/nrc3399

Esteller, 2000, Epigenetic lesions causing genetic lesions in human cancer: Promoter hypermethylation of DNA repair genes, Eur. J. Cancer, 36, 2294, 10.1016/S0959-8049(00)00303-8

Goode, 2002, Polymorphisms in DNA repair genes and associations with cancer risk, Cancer Epidemiol. Biomarkers Prev., 11, 1513

Maier, 2010, Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O(6)-methylguanine-DNA methyltransferase(P140K), Gene Ther., 17, 389, 10.1038/gt.2009.133

Blanc, 2004, Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas, J. Neurooncol., 68, 275, 10.1023/B:NEON.0000033385.37098.85

Rabik, 2008, Enhancement of cisplatin cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress, J. Pharmacol. Exp. Ther., 327, 442, 10.1124/jpet.108.141291

Gegi, 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma, N. Engl. J. Med., 352, 997, 10.1056/NEJMoa043331

Dong, X., Liu, R., and Chen, W. (2014). Correlation of promoter methylation in MGMT gene with glioma risk and prognosis: A meta-analysis. Mol. Neurobiol.

Frew, 2008, Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist, Proc. Natl. Acad. Sci. USA, 105, 11317, 10.1073/pnas.0801868105

Soria, 2010, Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumanb in patients with advanced non-squamous non-small-cell lung cancer, J. Clin. Oncol., 28, 1527, 10.1200/JCO.2009.25.4847

Mataga, 2012, Anti-breast cancer effects of histone deacetylase inhibitors and calpain inhibitors, Anticancer Res., 32, 2523

Sarkar, 2011, T-oligos inhibit growth and induce apoptosis in human ovarian cancer cells, Oligonucleoties, 21, 47, 10.1089/oli.2010.0259

Sarkar, 2013, Telomere-homilogous G-rich oligonucleotides sensitize human ovarian cancer cells by combination therapy, Nucleic Acid Ther., 23, 167, 10.1089/nat.2012.0401

Sasaki, 2010, Chloroquine potentiates the anticancer effect of 5-fluorouracil on colon cancer cells, BMC Cancer, 10, e370, 10.1186/1471-2407-10-370

Cook, 2014, Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer, Clin. Cancer Res., 20, 3222, 10.1158/1078-0432.CCR-13-3227

Shang, 2013, Roles of epithelial-mesenchymal transition in cancer drug resistance, Curr. Cancer Drug Targets, 13, 915, 10.2174/15680096113136660097

Singh, 2010, EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer, Oncogene, 29, 4741, 10.1038/onc.2010.215

Chaffer, 2011, Normal and neoplastic nonstem cells can spontaneously covert to a stem-like state, Proc. Natl. Acad. Sci. USA, 108, 7950, 10.1073/pnas.1102454108

Chaffer, 2011, A perspective on Cancer Cell Metastasis, Science, 331, 1559, 10.1126/science.1203543

Sarkar, 2013, Cancer development, progression and therapy: An epigenetic overview, Int. J. Mol. Sci., 14, 21087, 10.3390/ijms141021087

Byler, 2014, Genetic and epigenetic aspects of breast cancer progression and therapy, Anticancer Res., 34, 1071

Byler, 2014, Do epigenetic drug treatments hold the key to killing cancer progenitor cells?, Epigenomics, 6, 161, 10.2217/epi.14.4

Lenisak, 2009, Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer, Cancer Res., 69, 8620, 10.1158/0008-5472.CAN-09-1591

Sarkar, 2002, The role of AKT and RAFTK in beta1 integrin mediated survival of precursor B-acute lymphoblastic leukemia cells, Leuk. Lymphoma, 43, 1663, 10.1080/1042819021000003009

Wendt, 2010, Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression, Oncogene, 29, 6485, 10.1038/onc.2010.377

Carraway, 2006, Co-opted integrin signaling in ErbB2-induced mammary tumor progression, Cancer Cell, 10, 93, 10.1016/j.ccr.2006.07.015

Bates, 2005, The epithelial-mesenchymal transition (EMT) and colorectal cancer progression, Cancer Biol. Ther., 4, 365, 10.4161/cbt.4.4.1655

Galliher, 2006, β3 integrin and Src facilitate transforming growth factor-β mediated induction of epithelial-mesenchymal transition in mammary epithelial cells, Breast Cancer Res., 8, R42, 10.1186/bcr1524

Shibue, 2009, Integrin β1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs, Proc. Natl. Acad. Sci. USA, 106, 10290, 10.1073/pnas.0904227106

Witz, 2008, The selectin-selectin ligand axis in tumor progression, Cancer Metastasis Rev., 27, 19, 10.1007/s10555-007-9101-z

Paschos, 2009, The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis, Cell. Signal., 21, 665, 10.1016/j.cellsig.2009.01.006

Laubli, 2010, Selectins promote tumor metastasis, Semin. Cancer Biol., 20, 169, 10.1016/j.semcancer.2010.04.005

Desgrosellier, 2010, Integrins in cancer: Biological implications and therapeutic opportunities, Nat. Rev. Cancer, 10, 9, 10.1038/nrc2748

Bendas, G., and Borsig, L. (2012). Cancer cell adhesion and metastasis: Selectins, integrins, and the inhibitory potential of heparins. Int. J. Cell Biol., 2012.

Barkan, 2008, Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton, Cancer Res., 68, 6241, 10.1158/0008-5472.CAN-07-6849

Ning, 2014, Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy, Mol. Cancer Ther., 13, 528, 10.1158/1535-7163.MCT-13-0646

Bagot, 2012, Inducible expression and pathophysiologic functions of T-plastin in cutaneous T-cell lymphoma, Blood, 120, 143, 10.1182/blood-2011-09-379156

Staussman, 2012, Tumor micro-environment elicits innate resistance to RAF inhibitors through HGF secretion, Nature, 487, 500, 10.1038/nature11183

Parkin, 2013, Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia, Blood, 121, 369, 10.1182/blood-2012-04-427039

Navin, 2010, Inferring tumor progression from genomic heterogeneity, Genome Res., 20, 68, 10.1101/gr.099622.109

Campbell, 2010, The patterns and dynamics of genomic instability in metastatic pancreatic cancer, Nature, 467, 1109, 10.1038/nature09460

Baker, 2003, The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer, Exp. Cell Res., 290, 177, 10.1016/S0014-4827(03)00342-2

Kantharidis, 1997, Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance, Clin. Cancer Res., 3, 2025

Plumb, 2000, Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter, Cancer Res., 60, 6039

Arnold, 2003, Role of MLH1 promoter hypermethylation in drug resistance to 5-flurouracil in colorectal cancer cell lines, Int. J. Cancer, 106, 66, 10.1002/ijc.11176

Bearzatto, 2000, Epigenetic regulation of the MGMT and hMSH6 DNA repair genes in cells resistant to methylating agents, Cancer Res., 60, 3262

Esteller, 2000, Inactivation of DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents, N. Engl. J. Med., 343, 1350, 10.1056/NEJM200011093431901

Worm, 2001, Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells, J. Biol. Chem., 276, 39990, 10.1074/jbc.M103181200

Chang, 2005, Tamoxifen-resistant breast cancer show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene, J. Mol. Med., 83, 132, 10.1007/s00109-004-0596-2

Christmann, 2001, Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT, Int. J. Cancer, 92, 123, 10.1002/1097-0215(200102)9999:9999<::AID-IJC1160>3.0.CO;2-V

Izbicka, 1999, 5,6 Dihydro-5'-azacytidine (DHAC) restores androgen responsiveness in androgen-insensitive prostate cancer cells, Anticancer Res., 19, 1285

Sarkar, 2011, Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling, Anticancer Res., 31, 2723

Housman, G., Mataga, A.M., Devalapalli, A., Heerboth, S., Evans, L.R., and Sarkar, S. (, January April). Demethylation and re-expression of tumor suppressor genes by HDAC inhibitors and calpain inhibitors in cancer cells: A study related to synergistic type growth inhibition and reduction of motility. The Epigenetics World Congress, MA, USA. Abstract 206.

Sarkar, 2013, Demethylation and re-expression of epigenetically silenced tumor suppressor genes: Sensitization of cancer cells by combination therapy, Epigenomics, 5, 87, 10.2217/epi.12.68

Juergens, 2011, Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer, Cancer Discov., 1, 598, 10.1158/2159-8290.CD-11-0214

Johannessen, 2013, A melanocyte lineage program confers resistance to MAP kinase pathway inhibition, Nature, 504, 138, 10.1038/nature12688

Cacan, 2014, Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance, PLoS One, 9, e87455, 10.1371/journal.pone.0087455

Meyers, R.A. (2014). Encyclopedia of Analytical Chemistry, John Wiley.

Heerboth, 2014, The use of epigenetic drugs in diseases: An overview, Genet. Epigenet., 6, 9, 10.4137/GEG.S12270